New Webinar
Measuring suPAR in COVID-19 patients presents a valuable tool for improving risk stratification accuracy and helping to predict the risk of developing severe consequences of a COVID-19 infection. This was confirmed in a newly [...]
A suPAR level below 4ng/ml can be a useful discharge marker. suPAR cut-offs <4, between 4-6 and >6ng/ml can identify acute medical patients who have low, medium or high risk of 30- and 90-day mortality. [...]
Nikaia Hospital was build in 1932 and became a general hospital in 1952 (Fig. 1). The hospital has 615 beds and more than 1,700 staff members. It is one of the largest hospitals in the Athens-Piraeus region, covering the [...]
Dr Vasileios Kaldis is trained as a surgeon and intensive care specialist consultant. Currently, he is heading the Emergency Department (ED) at the Sismanoglio General Hospital, located in the Northern part of Athens in Greece (Fig. 1). [...]
Early start of anakinra treatment guided by suPAR provides 2.78 times better improvement of overall clinical status in patients with moderate and severe COVID-19 pneumonia SAVE-MORE is a multicenter, double-blinded, randomised controlled trial in [...]
ViroGates and Hellenic Institute for the Study of Sepsis announces positive topline results from the investigator-sponsored SAVE-MORE randomised controlled trial, evaluating early and targeted use of suPAR-guided anakinra treatment in over 600 patients. The [...]
Our annual report for 2020 has just been published In 2020, we made promising progress despite the challenging circumstances caused by the COVID-19 pandemic. We have been able to establish a more robust platform with [...]
suPAR on DR2 Our CEO Jakob Knudsen participated in an experiment for the Danish TV channel DR2, where he and a few others tested Wim Hof’s techniques, consisting of cold baths and breathing exercises that should strengthen the [...]
If you have any questions regarding our products or business, write to us here
